About Dimethyladenosine transferase 1, mitochondrial
Dimethyladenosine transferase 1, mitochondrial (TFB1M) is a protein
from Homo sapiens identified by UniProt accession
Q8WVM0, 346 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | Dimethyladenosine transferase 1, mitochondrial |
| UniProt accession | Q8WVM0 |
| Gene | TFB1M |
| Organism | Homo sapiens |
| Length | 346 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (47)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- Mitochondrial non-syndromic sensorineural deafness · score 0.37
- grip strength measurement · score 0.29
- self reported educational attainment · score 0.24
- mathematical ability · score 0.24
- cognitive function measurement · score 0.19
- appendicular lean mass · score 0.14
- body height · score 0.14
- sitting height measurement · score 0.13
- vital capacity · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WVM0-F1 | alphafold | PREDICTED | 91.93 | — |
Amino-acid sequence (346 residues)
MAASGKLSTC RLPPLPTIRE IIKLLRLQAA KQLSQNFLLD LRLTDKIVRK AGNLTNAYVY EVGPGPGGIT RSILNADVAE LLVVEKDTRF IPGLQMLSDA APGKLRIVHG DVLTFKVEKA FSESLKRPWE DDPPNVHIIG NLPFSVSTPL IIKWLENISC RDGPFVYGRT QMTLTFQKEV AERLAANTGS KQRSRLSVMA QYLCNVRHIF TIPGQAFVPK PEVDVGVVHF TPLIQPKIEQ PFKLVEKVVQ NVFQFRRKYC HRGLRMLFPE AQRLESTGRL LELADIDPTL RPRQLSISHF KSLCDVYRKM CDEDPQLFAY NFREELKRRK SKNEEKEEDD AENYRL
Explore Dimethyladenosine transferase 1, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets